Phage Therapy from Bench to Bedside: Collaborative Approaches to Personalized Treatment
Abstract
N/A
Kim MK, Suh GA, Cullen GD, Rodriguez SP, Dharmaraj T, Chang THW, et al. Bacteriophage therapy for multidrug-resistant infections: current technologies and therapeutic approaches. J Clin Invest. 2025;135(5):e187996.
Moon K, Coxon C, Årdal C, Botgros R, Djebara S, Durno L, et al. Considerations and perspectives on phage therapy from the transatlantic taskforce on antimicrobial resistance. Nat Commun. 2025;16(1):10883.
Sora VM, Wallet C, Meroni G, Loustau T, Rohr O, Zecconi A, Schwartz C. Antimicrobial Resistance: How Can We Overcome the Problem? Antibiotics (Basel). 2026;15(1):1-14.
Zhang S, Ahn J. Phage therapy as a novel alternative to antibiotics through adaptive evolution and fitness trade-offs. Antibiotics (Basel). 2025;14(10):1040.
Panagiotopoulos AP, Sagona AP, Tsakri D, Ferous S, Anastassopoulou C, Tsakris A. Virological and Pharmaceutical Properties of Clinically Relevant Phages. Antibiotics (Basel). 2025;14(5):487.
Pirnay JP, Djebara S, Steurs G, Griselain J, Cochez C, De Soir S, et al. Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study. Nat Microbiol. 2024;9(6):1434-53.
Uyttebroek S, Chen B, Onsea J, Ruythooren F, Debaveye Y, Devolder D, et al. Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. Lancet Infect Dis. 2022;22(8):e208-e20.
Niazi SK. Bacteriophage therapy: discovery, development, and FDA approval pathways. Pharmaceuticals (Basel). 2025;18(8):1115.
Fuerst-Wilmes M, Respondek V, Schramm M, Lilienthal N, Buss K, Duechting A. Regulation of phage therapy medicinal products: developments, challenges, and opportunities. Front Cell Infect Microbiol. 2025;15:1631359.
Fukaya-Shiba A, Ogata A, Kuribayashi R, Sakurai A, Suzuki K, Takadama S, et al. Regulatory considerations for developing phage therapy medicinal products for the treatment of antimicrobial resistant bacterial infections. Front Pharmacol. 2025;16:1713471.
Nagel T, Musila L, Muthoni M, Nikolich M, Nakavuma JL, Clokie MR. Phage banks as potential tools to rapidly and cost-effectively manage antimicrobial resistance in the developing world. Curr Opin Virol. 2022;53:101208.
| Files | ||
| Issue | Vol 13, No 4 (Autumn 2025) | |
| Section | Editorial | |
| Keywords | ||
| Phage therapy Antimicrobial Resistance Antibiotics | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
